Core Viewpoint - The article discusses the advancements and market potential of Hangzhou Dishi Medical Biotechnology Co., Ltd. in the field of surgical robotics, particularly focusing on its innovative micro-surgical robots that address unmet clinical needs and enhance surgical precision [2][5]. Group 1: Company Overview - Dishi Medical has completed a multi-million A2 round financing led by Dacheng Capital, with continued investment from Panlin Capital, aimed at accelerating the market adoption of its ultra-micro surgical robots [2]. - The company specializes in robotic micro-manipulation technology, focusing on ultra-micro surgical robots that can overcome the limitations of human hands, addressing significant clinical demands in the surgical field [2][5]. Group 2: Product Development and Innovation - Dishi Medical's ultra-micro technology allows for more stable and precise operations in complex retinal procedures, significantly reducing surgical damage and enabling the delivery of innovative drugs [5]. - The company has developed a range of products, including eye surgery robots, surgical simulation systems, instrument robots, micro-injection pumps, and micro-injection needles, continuously advancing its core technology platform [8]. Group 3: Market Potential and Impact - In China, there are over 40 million patients with retinal diseases, and cataract surgeries are projected to exceed 5 million by 2025, indicating a substantial market opportunity for Dishi Medical's products [5]. - The eye surgery robot has entered the National Medical Products Administration (NMPA) special review "green channel," making it the first eye surgery robot in China to achieve this status, which is expected to enhance its market presence [5][8]. Group 4: Clinical Achievements - Dishi Medical has successfully completed the first international robot-assisted deep cervical lymphatic-venous anastomosis and the first domestic superficial limb lymphatic-venous anastomosis, demonstrating superior stability and safety in complex surgical procedures [6].

Core Viewpoint - Recently, Hangzhou Disi Medical Biotechnology Co., Ltd. completed several million yuan in A2 round financing, led by Dacheng Caizhi, with existing shareholder Panlin Capital participating again. This funding will accelerate the market penetration of Disi Medical's ultra-microsurgery robots [1]. Group 1: Company Overview - Disi Medical focuses on the development of ultra-microsurgery robots, aiming to address unmet clinical needs in the field of microsurgery by overcoming the limitations of human hand operations [3]. - The company has launched a series of products, including ophthalmic surgical robots and microsurgery robots, and is actively pursuing a global strategy to benefit patients worldwide with its original ultra-microsurgery technology [7]. Group 2: Technological Advancements - Disi Medical's ultra-microsurgery technology allows for precise operations at the micron level, significantly reducing surgical damage and enabling the precise delivery of innovative drugs for retinal disease patients [3]. - The company has successfully completed the first robot-assisted lymphatic-venous anastomosis (LVA) reconstruction surgery in China, demonstrating superior stability and safety in addressing complex conditions like post-tumor lymphedema [5]. Group 3: Market Potential - The ultra-microsurgery robot segment is viewed as a blue ocean market within the surgical robotics field, with significant potential to meet the clinical demands of a large patient population, particularly in ophthalmology, where there are over 50 million patients with retinal diseases in China [3].